NEW YORK--(BUSINESS WIRE)--

Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company will be featured on RedChip Real Radio(TM) Monday, May 19, 2008, at 9:00AM EDT. Pluristem's Senior Vice President Corporate Development, William Prather RPh, MD, will be interviewed. RedChip Real Radio(TM) is a daily financial program with nationally known radio personality, Gary McKenzie, that features small-cap companies from around the country.

RedChip Real Radio(TM) can be heard every trading day from 9 a.m. to 10 a.m. EDT and every evening from 6 p.m. to 7 p.m. EDT on Washington Business Radio 700 AM. The show can also be heard live on RedChip's international online audio stream at www.redchip.com. The financial talk show features exclusive CEO interviews with hosts Dave Gentry, President and CEO of RedChip Companies, Inc., and Gary McKenzie, a nationally known financial talk show host and former CBS Radio Network anchor.

Mr. Zami Aberman, Pluristem's President & CEO, stated: "We are pleased that RedChip Real Radio has decided to feature us on their program and allow the investment community to learn about our unique and innovative cellular therapeutics business model."

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; PLX-STROKE, targeting ischemic stroke; PLX-MS, targeting Multiple Sclerosis; and PLX-IBD, targeting patients suffering from Inflammatory Bowel Disease (IBD), which includes Crohn's disease and Ulcerative Colitis.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

    See our product animation on YouTube:

    http://www.youtube.com/watch?v=OFhWXyJT6Us.

    Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Source: Pluristem Therapeutics Inc.